Antibody Responses to Fusobacterium nucleatum Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer
Butt, Julia; Jenab, Mazda; Pawlita, Michael; Overvad, Kim; Tjonneland, Anne; Olsen, Anja; Boutron-Ruault, Marie-Christine; Carbonnel, Franck; Mancini, Francesca Romana; Kaaks, Rudolf; Kühn, Tilman; Boeing, Heiner; Trichopoulou, Antonia; Karakatsani, Anna; Palli, Domenico; Pala, Valeria Maria; Tumino, Rosario; Sacerdote, Carlotta; Panico, Salvatore; Bueno-de-Mesquita, Bas; van Gils, Carla H; Vermeulen, Roel C H; Weiderpass, Elisabete; Quirós, José Ramón; Duell, Eric Jeffrey; Sánchez, Maria-Jose; Dorronsoro, Miren; Huerta, José María; Ardanaz, Eva; Van Guelpen, Bethany; Harlid, Sophia; Perez-Cornago, Aurora; Gunter, Marc J; Murphy, Neil; Freisling, Heinz; Aune, Dagfinn; Waterboer, Tim; Hughes, David J
(2019) Cancer Epidemiology Biomarkers & Prevention, volume 28, issue 9, pp. 1552 - 1555
(Article)
Abstract
BACKGROUND: There is a lack of prospective data on the potential association of Fusobacterium nucleatum (F. nucleatum) and colorectal cancer risk. In this study, we assessed whether antibody responses to F. nucleatum are associated with colorectal cancer risk in prediagnostic serum samples in the European Prospective Investigation into Nutrition and
... read more
Cancer (EPIC) cohort. METHODS: We applied a multiplex serology assay to simultaneously measure antibody responses to 11 F. nucleatum antigens in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CI). RESULTS: We observed neither a statistically significant colorectal cancer risk association for antibodies to individual F. nucleatum proteins nor for combined positivity to any of the 11 proteins (OR, 0.81; 95% CI, 0.62-1.06). CONCLUSIONS: Antibody responses to F. nucleatum proteins in prediagnostic serum samples from a subset of colorectal cancer cases and matched controls within the EPIC study were not associated with colorectal cancer risk. IMPACT: Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Journal Article
ISSN: 1055-9965
Publisher: American Association for Cancer Research Inc.
Note: Funding Information: We thank Ute Koch, Monika Oppenl€ander, and Claudia Brandel for excellent technical assistance with the serological measurements. D.J. Hughes was supported by the Health Research Board of Ireland project grants HRA_PHS/2013/ 397 and HRA_PHS/2015/1142. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Funding Information: We thank Ute Koch, Monika Oppenl?ander, and Claudia Brandel for excellent technical assistance with the serological measurements. D.J. Hughes was supported by the Health Research Board of Ireland project grants HRA_PHS/2013/397 and HRA_PHS/2015/1142. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Publisher Copyright: © 2019 American Association for Cancer Research.
(Peer reviewed)